JP2016508145A5 - - Google Patents

Download PDF

Info

Publication number
JP2016508145A5
JP2016508145A5 JP2015551200A JP2015551200A JP2016508145A5 JP 2016508145 A5 JP2016508145 A5 JP 2016508145A5 JP 2015551200 A JP2015551200 A JP 2015551200A JP 2015551200 A JP2015551200 A JP 2015551200A JP 2016508145 A5 JP2016508145 A5 JP 2016508145A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
group
inhibitor
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015551200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508145A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/050166 external-priority patent/WO2014108407A1/en
Publication of JP2016508145A publication Critical patent/JP2016508145A/ja
Publication of JP2016508145A5 publication Critical patent/JP2016508145A5/ja
Pending legal-status Critical Current

Links

JP2015551200A 2013-01-08 2014-01-07 ピリドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用 Pending JP2016508145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750023P 2013-01-08 2013-01-08
US61/750,023 2013-01-08
PCT/EP2014/050166 WO2014108407A1 (en) 2013-01-08 2014-01-07 Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (2)

Publication Number Publication Date
JP2016508145A JP2016508145A (ja) 2016-03-17
JP2016508145A5 true JP2016508145A5 (enExample) 2017-02-16

Family

ID=50070508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015551200A Pending JP2016508145A (ja) 2013-01-08 2014-01-07 ピリドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用

Country Status (11)

Country Link
US (1) US8952039B2 (enExample)
EP (1) EP2943469A1 (enExample)
JP (1) JP2016508145A (enExample)
KR (1) KR20150103034A (enExample)
CN (1) CN104903294A (enExample)
BR (1) BR112015016184A2 (enExample)
CA (1) CA2894452A1 (enExample)
HK (2) HK1211287A1 (enExample)
MX (1) MX2015008288A (enExample)
RU (1) RU2015125570A (enExample)
WO (1) WO2014108407A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709321A (zh) 2015-04-28 2018-02-16 盐野义制药株式会社 经取代的多环性吡啶酮衍生物及其前药
HK1254961A1 (en) 2015-12-15 2019-08-02 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
US10676428B2 (en) 2015-12-17 2020-06-09 Ramot At Tel-Aviv University Ltd. Antiviral agents for amantadine-resistant influenza A
US10889556B2 (en) * 2016-03-08 2021-01-12 The Regents Of The University Of California Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease
US10759814B2 (en) 2016-08-10 2020-09-01 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
AU2005211349A1 (en) 2004-01-30 2005-08-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
US20070072831A1 (en) 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
US8835461B2 (en) * 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Similar Documents

Publication Publication Date Title
JP2016518305A5 (enExample)
JP2015517555A5 (enExample)
JP2015521189A5 (enExample)
JP2014530838A5 (enExample)
RU2014143250A (ru) Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
RU2014120421A (ru) Производные гетероарилгидроксамовой кислоты и их применение при лечении, облегчении течения или профилактике вирусных заболеваний
RU2014146778A (ru) Производные 7-оксо-4,7-дигидропиразоло[1,5-а]пиримидина, которые пригодны для лечения, уменьшения интенсивности или предупреждения вирусного заболевания
JP2016121196A5 (enExample)
JP2014521688A5 (enExample)
PH12020551264A1 (en) Pyridone Derivative, Composition And Use As Antiviral Drug Thereof
JP2013010792A5 (enExample)
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
JP2017518959A5 (enExample)
JP2017531038A5 (enExample)
JP2015524457A5 (enExample)
JP2015051983A5 (enExample)
JP2020507589A5 (enExample)
JP2016503797A5 (enExample)
JP2015535839A5 (enExample)
RU2015125570A (ru) Пиридоновые производные и их применение в лечении, уменьшении интенсивности симптомов или предотвращении вирусного заболевания
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
JP2018530582A5 (enExample)
AR089397A1 (es) Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica
JP2016504376A5 (enExample)